Top News Stories November 28 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 28 2017”

Adamis Pharmaceuticals Could Explode Over 130 Percent

Adamis Pharmaceuticals is looking at various licensing partners for its FDA approved Symjepi which will compete against Mylan’s EpiPen. As soon as the company announces a licensing partner, this stock could explode over 130 percent higher.

Adamis Pharmaceuticals was given a $10 price target by analysts at B. Riley last week. B. Riley has a Buy rating on the stock. Overall, the stock has no Sell ratings and 3 Buy ratings. The average target price is $10 which represents 138% upside from the current price of $4.20.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Intercept Pharmaceuticals Rising Large Players Volume

Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.

Intercept Pharmaceuticals has rising large players volume while the stock has formed a basing pattern. This is a very bullish technical setup.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Bluebird Bio Stock Strong Uptrend On Buy Ratings

While Bluebird Bio stock doesn’t look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.

Bluebird Bio stock is in a strong uptrend as the number of analysts with Buy ratings surge.

BTIG upgraded Bluebird Bio stock from Neutral to Buy, and set a price target of $177. BTIG thinks that positive signals are coming from the FDA concerning bluebird bio's latest CAR-T therapy for advanced stage multiple myeloma patients. Earlier this year, bluebird bio's precursor to bb21217, named bb2121, delivered a 100% response rate among 15 multiple myeloma patients.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Abbott Laboratories Gets FDA Clearance for its Alinity

We have been stalking Abbott Laboratories for an entry. With FDA clearance of its Alinity mobile blood test unit and recent pullback, now may be the time for an entry.

Abbott Laboratories gets FDA 510(k) clearance for its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics.

Brian Blaser, Executive Vice President, said, "Healthcare systems across the United States are under pressure to deliver better care for patients. Labs and healthcare systems are looking for complete solutions that help them operate more efficiently while contributing to better clinical decision making and helping improve patient outcomes."

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Exelixis Candle Over Candle Swing Trade Setup

Exelixis stock has done a candle over candle reversal off of its uptrend line support which looks like a good swing trade setup.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Sorrento Therapeutics Inc Bounce Off 61.8 Percent Retracement

Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Verastem Inc Price Target Raised By Cantor Fitzgerald

Verastem Inc price target was raised to $17 by Cantor Fitzgerald last week. The new $17 price target represents 330% upside from the previous close of $3.95. Cantor has a Buy rating on the stock.

Cantor Fitzgerald is respected on Wall Street but they do not have the most accurate analysts IMO. Oppenheimer Holdings Inc is a more followed analyst than Cantor Fitzgerald. It's no surprise then that I think it's more significant that on October 12, 2017, Oppenheimer reiterated their Buy rating on Verastem Inc stock and set a price target of $6 which represents an upside of 52% from the previous close. The $6 price target seems more down-to-earth and achievable than Cantor's stratospheric $17 price target.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Transenterix Stock 50 Percent Retracement After FDA Approval

Transenterix stock is coming off a 50 percent retracement after the stock exploded higher from FDA approval of its Senhance Robotic Surgical System. This is the first FDA surgical robotic system approval in two decades.

Where Sehance Robotic Surgical System beats Intuitive Surgical's da Vinci system is in the fully reusable instruments, which promises to vastly lower the per-procedure cost of robotic surgery.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Exelixis Gets FDA Priority Review for Cabomteyx

The FDA has granted priority review for Exelixis Cabomteyx. The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA determined the sNDA to be sufficiently complete. This means an FDA approval decision will be made by Feb. 15, 2018.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.